EU's CHMP gives accelerated go-ahead for Eisai's lenvatinib
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended approval of Eisai's Lenvima (lenvatinib) for the treatment of adults with progressive, locally advanced or metastatic differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma, whose disease has progressed despite receiving radioactive iodine.